May 16, 2025 · Form 4 insider transaction
Calkins Daniel sold 38,850 shares of VSTM at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.